Company intelligence / Profile preview

CNSCo

Bethesda, Maryland, United States

Ownership: Private
Development stage: Other

Overview

CNSCo was a Maryland-based biotechnology company focused on the development of novel therapies for central nervous system (CNS) disorders and pain management. Founded by Dr. John Holaday, a prominent biotech entrepreneur, the company specialized in optimizing opioid therapy through its Dual Opioid platform, which combined morphine and oxycodone to enhance efficacy while reducing side effects. In 2007, CNSCo merged with the Australian firm QRxPharma to form a trans-Pacific pharmaceutical company, facilitating an IPO on the Australian Securities Exchange. The company's portfolio also included proprietary abuse-deterrent technologies and research into dystonia-related proteins like Torsin.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Queensland

Beyond the preview

Go deeper on CNSCo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNSCo.

Explore the full profile